Data gathered: December 26
AI Stock Analysis - Acumen Pharmaceuticals (ABOS)
Analysis generated October 29, 2024. Powered by Chat GPT.
Acumen Pharmaceuticals is a biotechnology firm that focuses on the development and commercialization of therapeutics to address unmet medical needs. The company's strategy involves rigorous scientific and regulatory approaches, emphasizing innovative and evidence-based solutions. Despite the high potential in the biotech sector, companies like Acumen are subject to considerable financial risks and benefits related to their product pipeline, regulatory approvals, and market adoption.
Stock Alerts - Acumen Pharmaceuticals (ABOS)
 |
Acumen Pharmaceuticals | December 18 Price is down by -6.6% in the last 24h. |
|
Acumen Pharmaceuticals | December 13 Price is down by -5.3% in the last 24h. |
|
Acumen Pharmaceuticals | December 12 Price is down by -5.1% in the last 24h. |
|
Acumen Pharmaceuticals | December 11 Price is down by -5.1% in the last 24h. |
Alternative Data for Acumen Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 92 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 3 | Sign up | Sign up | Sign up |
| Facebook Followers | 2,353 | Sign up | Sign up | Sign up |
| Instagram Followers | 116 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,110 | Sign up | Sign up | Sign up |
| Twitter Followers | 254 | Sign up | Sign up | Sign up |
| Twitter Mentions | 35 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 63 | Sign up | Sign up | Sign up |
About Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease.
| Price | $1.79 |
| Target Price | Sign up |
| Volume | 363,190 |
| Market Cap | $108M |
| Year Range | $1.77 - $3.84 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Franklin Resources Inc. Acquires 181,451 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)December 23 - ETF Daily News |
 |
Reviewing MeiraGTx (NASDAQ:MGTX) & Acumen Pharmaceuticals (NASDAQ:ABOS)December 19 - ETF Daily News |
|
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest UpdateDecember 18 - ETF Daily News |
|
Head to Head Comparison: Genetic Technologies (NASDAQ:GENE) & Acumen Pharmaceuticals (NASDAQ:ABOS)December 7 - ETF Daily News |
 |
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNovember 26 - Yahoo |
|
Contrasting Neurocrine Biosciences (NASDAQ:NBIX) and Acumen Pharmaceuticals (NASDAQ:ABOS)November 24 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 100,000 | 5M | -4.9M | -30M | 0 | 0.000 |
| Q2 '24 | 0 | 4.8M | -4.8M | -21M | -24M | -0.340 |
| Q1 '24 | 3M | 5.3M | -2.3M | -15M | -18M | -0.250 |
| Q4 '23 | 10M | 5.2M | 5M | -16M | -18M | -0.280 |
| Q3 '23 | 0 | 4.9M | -4.9M | -13M | -16M | -0.240 |
Insider Transactions View All
| Meisner Derek M filed to sell 108,867 shares at $3.5. January 19 '24 |
| OConnell Daniel Joseph filed to sell 502,485 shares at $3.5. January 19 '24 |
| Barton Russell filed to sell 96,867 shares at $3.7. January 19 '24 |
| Siemers Eric filed to sell 117,576 shares at $3.7. January 19 '24 |
| Zuga Matt filed to sell 211,445 shares at $3.7. January 19 '24 |
Similar companies
Read more about Acumen Pharmaceuticals (ABOS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Acumen Pharmaceuticals?
The Market Cap of Acumen Pharmaceuticals is $108M.
What is the current stock price of Acumen Pharmaceuticals?
Currently, the price of one share of Acumen Pharmaceuticals stock is $1.79.
How can I analyze the ABOS stock price chart for investment decisions?
The ABOS stock price chart above provides a comprehensive visual representation of Acumen Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Acumen Pharmaceuticals shares. Our platform offers an up-to-date ABOS stock price chart, along with technical data analysis and alternative data insights.
Does ABOS offer dividends to its shareholders?
As of our latest update, Acumen Pharmaceuticals (ABOS) does not offer dividends to its shareholders. Investors interested in Acumen Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Acumen Pharmaceuticals?
Some of the similar stocks of Acumen Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.